Pulmonary Vascular Disease News

The FDA announced approval of selexipag for treatment of patients with pulmonary arterial hypertension.

Intrapulmonary vascular dilatations occurred more commonly in patients with portopulmonary hypertension and were associated with decreased overall survival, according to study data published in Liver Transplantation.

Favorable short-term outcomes of patients with pulmonary embolisms after hospital discharge suggest these patients can safely receive outpatient treatment, according to study results.

Various prediction rules physicians used to determine early mortality in patients with acute pulmonary embolism had high sensitivity rates, for the most part, but relatively low specificity rates, according to study results.

Patients with idiopathic pulmonary arterial hypertension who responded to an acute vasodilator challenge had fewer baseline hemodynamic abnormalities compared with nonresponders, according to a research letter published in Annals of Internal Medicine.

Treatment with a 10-mg dose of macitentan significantly decreased the risk for and prevalence of all-cause hospitalization among patients with symptomatic pulmonary arterial hypertension, according to findings from the SERAPHIN study.

In patients with pulmonary arterial hypertension, first-line therapy with a combination of ambrisentan and tadalafil reduced the risk for clinical failure compared with monotherapy with either drug, according to findings presented at ERS International Congress 2014.

Coenzyme Q10 supplementation improved hemoglobin and red cell maturation in patients with pulmonary arterial hypertension, which could confer clinical benefit, according to findings in a new study.

LOS ANGELES — Early diagnosis of pulmonary arterial hypertension is crucial for improving patient outcomes, according to Glenna Traiger, RN, MSN, CNS-BC from the University of California at Los Angeles, who presented at the American Association of Heart Failure Nurses Annual Conference.